Showing results (1-10 of 336) with videos related to
Sort By:
Pageof 34
Human Reproduction (Oxford, England)|May 28, 2005
Effects of slow release misoprostol on uterine contractility in early pregnancyC Fiala, A Aronsson, O Stephansson, et al.Human Reproduction (Oxford, England)|August 2, 2005
The effect of non-steroidal anti-inflammatory drugs on medical abortion with mifepristone and misoprostol at 13-22 weeks gestationC Fiala, M L Swahn, O Stephansson, et al.Human Reproduction (Oxford, England)|February 23, 2010
Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 daysH Kopp Kallner, C Fiala, O Stephansson, et al.International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|October 27, 2007
Cervical priming with misoprostol prior to transcervical proceduresC Fiala, K Gemzell-Danielsson, O S Tang, et al.Human Reproduction Update|May 15, 2013
Management of pain associated with the insertion of intrauterine contraceptivesK Gemzell-Danielsson, D Mansour, C Fiala, et al.The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception|December 2, 2005
Home use of two doses of misoprostol after mifepristone for medical abortion: a pilot study in Sweden and FranceW H Clark, D Hassoun, K Gemzell-Danielsson, et al.Human Reproduction (Oxford, England)|December 1, 2011
Effect of bacterial vaginosis on the pharmacokinetics of misoprostol in early pregnancyA Sioutas, A Sandström, C Fiala, et al.Minerva Ginecologica|June 20, 2006
Effects of levonorgestrel on ovarian function when used for emergency contraceptionK Gemzell-DanielssonBJOG : an International Journal of Obstetrics and Gynaecology|September 1, 2017
Efficacy and safety of very early medical termination of pregnancy: a cohort studyI Bizjak, C Fiala, L Berggren, et al.Human Reproduction (Oxford, England)|May 10, 2007
Pharmacokinetic profiles up to 12 h after administration of vaginal, sublingual and slow-release oral misoprostolA Aronsson, C Fiala, O Stephansson, et al.Pageof 34